TrialJapanese journal of clinical oncology2017

Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study.

Yoshihiko Tomita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.